PJA1

Summary

PJA1 (praja ring finger ubiquitin ligase 1, HGNC:16648) is a protein-coding gene on chromosome Xq13.1, encoding E3 ubiquitin-protein ligase Praja-1 (Q8NG27). Has E2-dependent E3 ubiquitin-protein ligase activity.

This gene encodes an enzyme that has E2-dependent E3 ubiquitin-protein ligase activity. This enzyme belongs to a class of ubiquitin ligases that include a RING finger motif, and it can interact with the E2 ubiquitin-conjugating enzyme UbcH5B. This gene is located in an area of chromosome X where several X-linked cognitive disability disorders have been associated, and it has also been found as part of a contiguous gene deletion associated with craniofrontonasal syndrome, though a direct link to any disorder has yet to be demonstrated. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 64219 — RefSeq curated summary.

At a glance

• Gene–disease (curated): X-linked complex neurodevelopmental disorder (Moderate, GenCC)
• GWAS associations: 6
• Clinical variants (ClinVar): 96 total
• MANE Select transcript: NM_001032396

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16648
Approved symbol	PJA1
Name	praja ring finger ubiquitin ligase 1
Location	Xq13.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ11830, RNF70, PRAJA1
Ensembl gene	ENSG00000181191
Ensembl biotype	protein_coding
OMIM	300420
Entrez	64219

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 7 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000361478, ENST00000374571, ENST00000374583, ENST00000374584, ENST00000471141, ENST00000477231, ENST00000590146, ENST00000901511

RefSeq mRNA: 5 — MANE Select: NM_001032396 NM_001032396, NM_001382775, NM_001382776, NM_022368, NM_145119

CCDS: CCDS14392, CCDS14393, CCDS35316

Canonical transcript exons

ENST00000374571 — 2 exons

Exon	Start	End
ENSE00001463848	69160861	69163140
ENSE00002894178	69165372	69165453

Expression profiles

Bgee: expression breadth ubiquitous, 271 present calls, max score 97.93.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 15.7009 / max 364.7686, expressed in 1757 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
199523	14.3863	1750
199524	1.3146	724

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	97.93	gold quality
ganglionic eminence	UBERON:0004023	97.63	gold quality
corpus epididymis	UBERON:0004359	97.46	gold quality
ventricular zone	UBERON:0003053	97.20	gold quality
embryo	UBERON:0000922	96.11	gold quality
nucleus accumbens	UBERON:0001882	95.20	gold quality
middle temporal gyrus	UBERON:0002771	94.30	gold quality
anterior cingulate cortex	UBERON:0009835	94.09	gold quality
cingulate cortex	UBERON:0003027	94.01	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	93.91	gold quality
prefrontal cortex	UBERON:0000451	93.62	gold quality
Brodmann (1909) area 9	UBERON:0013540	93.59	gold quality
caudate nucleus	UBERON:0001873	93.42	gold quality
hypothalamus	UBERON:0001898	93.33	gold quality
neocortex	UBERON:0001950	92.98	gold quality
islet of Langerhans	UBERON:0000006	92.96	gold quality
putamen	UBERON:0001874	92.78	gold quality
right frontal lobe	UBERON:0002810	92.78	gold quality
frontal cortex	UBERON:0001870	92.67	gold quality
cerebral cortex	UBERON:0000956	92.63	gold quality
amygdala	UBERON:0001876	92.61	gold quality
telencephalon	UBERON:0001893	92.56	gold quality
forebrain	UBERON:0001890	92.24	gold quality
brain	UBERON:0000955	91.49	gold quality
temporal lobe	UBERON:0001871	91.31	gold quality
Brodmann (1909) area 46	UBERON:0006483	91.02	gold quality
Ammon’s horn	UBERON:0001954	91.00	gold quality
adenohypophysis	UBERON:0002196	90.54	gold quality
cerebellar vermis	UBERON:0004720	90.12	gold quality
superior frontal gyrus	UBERON:0002661	89.93	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.08

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MYOD1

miRNA regulators (miRDB)

35 targeting PJA1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-4310	99.59	68.84	2527
HSA-MIR-2053	99.57	69.15	1635
HSA-MIR-3942-3P	99.57	69.03	2854
HSA-MIR-17-3P	99.55	66.77	1311
HSA-MIR-105-5P	99.54	69.24	2060
HSA-MIR-7853-5P	99.54	69.30	2055
HSA-MIR-208A-5P	99.42	70.83	1913
HSA-MIR-208B-5P	99.42	70.83	1952
HSA-MIR-100-3P	99.20	67.33	672
HSA-MIR-4520-2-3P	99.14	69.28	1009
HSA-MIR-4752	98.71	68.04	833
HSA-MIR-7850-5P	98.12	67.28	1111
HSA-MIR-509-3P	98.12	67.25	612
HSA-MIR-876-5P	97.99	68.49	1345
HSA-MIR-5088-5P	97.97	64.28	487
HSA-MIR-4275	97.96	68.42	1549

Literature-anchored findings (GeneRIF, showing 10)

• A RING finger protein Praja1 regulates Dlx5-dependent transcription through its ubiquitin ligase activity for the Dlx/Msx-interacting MAGE/Necdin family protein, Dlxin-1. (PMID:11959851)
• Involved in protein ubiquitination in the brain. Candidate gene for X-linked mental retardation. (PMID:12036302)
• Data provide clues into novel aspects of Praja1 function. (PMID:21461837)
• these results suggest a role for PRAJA1 in regulating the level of PRC2 by targeting its free subunits for Ub-mediated proteasomal degradation. (PMID:21513699)
• Targeting the E3 Ubiquitin Ligase PJA1 Enhances Tumor-Suppressing TGFbeta Signaling. (PMID:32127355)
• A recurrent PJA1 variant in trigonocephaly and neurodevelopmental disorders. (PMID:32530565)
• Praja1 RING-finger E3 ubiquitin ligase suppresses neuronal cytoplasmic TDP-43 aggregate formation. (PMID:32686212)
• E3 ubiquitin ligase PJA1 regulates lung adenocarcinoma apoptosis and invasion through promoting FOXR2 degradation. (PMID:33839405)
• Praja1 ubiquitin ligase facilitates degradation of polyglutamine proteins and suppresses polyglutamine-mediated toxicity. (PMID:34161122)
• PJA1-mediated suppression of pyroptosis as a driver of docetaxel resistance in nasopharyngeal carcinoma. (PMID:38906860)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	pja2	ENSDARG00000100296
mus_musculus	Pja1	ENSMUSG00000034403
rattus_norvegicus	Pja1	ENSRNOG00000047339

Paralogs (1): PJA2 (ENSG00000198961)

Protein

Protein identifiers

E3 ubiquitin-protein ligase Praja-1 — Q8NG27 (reviewed: Q8NG27)

Alternative names: RING finger protein 70, RING-type E3 ubiquitin transferase Praja-1

All UniProt accessions (3): Q8NG27, K7EPI8, K7EPW5

UniProt curated annotations — full annotation on UniProt →

Function. Has E2-dependent E3 ubiquitin-protein ligase activity. Ubiquitinates MAGED1 antigen leading to its subsequent degradation by proteasome. May be involved in protein sorting.

Subunit / interactions. Binds ubiquitin-conjugating enzymes (E2s). In vitro, interacts with the ubiquitin-conjugating enzyme, UBE2D2.

Tissue specificity. Expressed in various regions of the brain including the cerebellum, cerebral cortex, medulla, occipital pole, frontal lobe, temporal lobe and putamen. Highest levels in the cerebral cortex.

Post-translational modifications. Substrate for E2-dependent ubiquitination.

Domain organisation. The RING-type zinc finger domain interacts with an ubiquitin-conjugating enzyme (E2) and facilitates ubiquitination.

Miscellaneous. PubMed:12036302 reported that isoform 2 arises by alternative initiation.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8NG27-1	1	yes
Q8NG27-2	2, PJA1-beta, Praja1-beta
Q8NG27-3	3

RefSeq proteins (5): NP_001027568, NP_001369704, NP_001369705, NP_071763, NP_660095 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001841	Znf_RING	Domain
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily

Pfam: PF13639

UniProt features (30 total): compositionally biased region 8, strand 5, modified residue 4, turn 3, splice variant 2, sequence variant 2, region of interest 2, helix 2, chain 1, zinc finger region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2L0B	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NG27-F1	50.15	0.07

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 265, 277, 365, 367

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-983168	Antigen processing: Ubiquitination & Proteasome degradation

MSigDB gene sets: 149 (showing top): REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GGGTGGRR_PAX4_03, MARTINEZ_RB1_TARGETS_UP, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, HP1SITEFACTOR_Q6, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, EGR1_01, BREDEMEYER_RAG_SIGNALING_NOT_VIA_ATM_UP, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_DN, GOBP_PROTEIN_CATABOLIC_PROCESS, TAATTA_CHX10_01, MARSON_BOUND_BY_FOXP3_UNSTIMULATED

GO Biological Process (2): protein ubiquitination (GO:0016567), protein catabolic process (GO:0030163)

GO Molecular Function (5): zinc ion binding (GO:0008270), ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (1): cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Class I MHC mediated antigen processing & presentation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein modification by small protein conjugation	1
macromolecule catabolic process	1
protein metabolic process	1
transition metal ion binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
binding	1
catalytic activity	1
cation binding	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

840 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PJA1	MAGED1	Q9Y5V3	992
PJA1	OPHN1	O60890	828
PJA1	NDN	Q99608	789
PJA1	EFNB1	P98172	715
PJA1	UBE2D2	P51669	639
PJA1	MAGEA1	P43355	515
PJA1	MAGEB18	Q96M61	417
PJA1	NSMCE3	Q96MG7	406
PJA1	SMURF2	Q9HAU4	388
PJA1	EPHB1	P54762	386
PJA1	GINM1	Q9NU53	363
PJA1	EPHB4	P54760	360
PJA1	YIPF6	Q96EC8	327
PJA1	MAGEF1	Q9HAY2	324
PJA1	SMC5	Q8IY18	322

IntAct

60 interactions, top by confidence:

A	B	Type	Score
PJA1	MAGED1	psi-mi:“MI:0915”(physical association)	0.740
MAGED1	PJA1	psi-mi:“MI:0915”(physical association)	0.740
MAGED1	PJA1	psi-mi:“MI:0403”(colocalization)	0.740
NSMCE3	PJA1	psi-mi:“MI:0914”(association)	0.710
NSMCE3	PJA1	psi-mi:“MI:0915”(physical association)	0.710
PJA1	SMC5	psi-mi:“MI:0914”(association)	0.530
SKP2	DPYSL4	psi-mi:“MI:0914”(association)	0.530
CPA6	PPM1G	psi-mi:“MI:0914”(association)	0.530
LRRC27	HMOX1	psi-mi:“MI:0914”(association)	0.530
SPSB2	ARHGEF10	psi-mi:“MI:0914”(association)	0.530
SPSB4	ARHGEF10	psi-mi:“MI:0914”(association)	0.530
SMAD3	FAM83G	psi-mi:“MI:0915”(physical association)	0.400
PJA1	UBE2U	psi-mi:“MI:0915”(physical association)	0.370
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
AP2M1	C1orf226	psi-mi:“MI:0914”(association)	0.350
IQCN	TARSL2	psi-mi:“MI:0914”(association)	0.350
HNRNPLL	TBX3	psi-mi:“MI:0914”(association)	0.350
DOCK5	DPYSL4	psi-mi:“MI:0914”(association)	0.350
LRRC27	HMOX1	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
ARRDC2	ZSWIM8	psi-mi:“MI:0914”(association)	0.350
TXNIP	ZSWIM8	psi-mi:“MI:0914”(association)	0.350
MYO9B	PPM1G	psi-mi:“MI:0914”(association)	0.350
FBXO10	BLTP3B	psi-mi:“MI:0914”(association)	0.350
IQCN	TARS3	psi-mi:“MI:0914”(association)	0.350
DUSP16	MEIOC	psi-mi:“MI:0914”(association)	0.350

BioGRID (179): PJA1 (Biochemical Activity), PJA1 (Affinity Capture-MS), PJA1 (Affinity Capture-MS), PJA1 (Affinity Capture-MS), PJA1 (Affinity Capture-MS), PJA1 (Affinity Capture-MS), PJA1 (Affinity Capture-MS), PJA1 (Affinity Capture-MS), PJA1 (Affinity Capture-MS), PJA1 (Affinity Capture-MS), PJA1 (Affinity Capture-MS), PJA1 (Affinity Capture-MS), PJA1 (Affinity Capture-MS), PJA1 (Proximity Label-MS), PJA1 (Affinity Capture-MS)

ESM2 similar proteins: A0A140LFM6, A0A1B0GVH6, A1A4G5, A1CQN6, A7A241, A9RNY0, B0QZF7, B9UYK6, E9Q309, H0WFA5, O23372, O35413, O94875, P02686, P43587, Q0VFP3, Q0WL69, Q12912, Q17QQ9, Q1G3K8, Q32KY7, Q3UTJ2, Q499E5, Q4R309, Q4R881, Q4V7T5, Q56WM6, Q5E9A0, Q5PPL1, Q5R6I3, Q5VT06, Q62417, Q6AYU0, Q6DD19, Q6GP48, Q6H7U2, Q8K2H1, Q8L4M6, Q8NEY8, Q8NG27

Diamond homologs: A5WWA0, A8Y4B2, E9QAU8, O00237, O22197, O22283, O43085, O54965, O55176, O64763, P0CH03, P0CH30, P0DPR2, P87119, P90859, Q08CG8, Q08D68, Q0II22, Q2KHN1, Q3T0W3, Q3U2C5, Q3UHJ8, Q4KLR8, Q4V7B8, Q566M8, Q5DTZ6, Q5M974, Q5QLR5, Q5RBT7, Q5SPX3, Q5SSZ7, Q5XHH7, Q66HG0, Q6AXU4, Q6DIP3, Q6GPV5, Q6IRP0, Q6NPT7, Q6NRL6, Q6NRX0

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
PJA1	down-regulates	SPTBN1	ubiquitination
Ub:E2	“up-regulates activity”	PJA1	ubiquitination
PJA1	“down-regulates activity”	SMAD3	ubiquitination
PJA1	“down-regulates quantity by destabilization”	EZH2	ubiquitination
MYOD1	“up-regulates quantity”	PJA1	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

96 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	53
Likely benign	14
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

22 predictions. Top by Δscore:

Variant	Effect	Δscore
X:69163421:T:A	donor_gain	0.8900
X:69163501:CAAGA:C	donor_gain	0.3500
X:69162382:C:CA	acceptor_gain	0.3400
X:69163428:AGG:A	donor_gain	0.3300
X:69162383:T:A	acceptor_gain	0.3100
X:69163497:A:AC	donor_gain	0.3000
X:69162382:C:CC	acceptor_gain	0.2800
X:69162381:ACTGT:A	acceptor_gain	0.2600
X:69163418:CTTT:C	donor_gain	0.2500
X:69163531:A:AC	donor_gain	0.2400
X:69162381:A:AC	acceptor_gain	0.2300
X:69163417:A:AC	donor_gain	0.2300
X:69163418:C:CC	donor_gain	0.2300
X:69162408:A:T	acceptor_gain	0.2200
X:69163419:T:C	donor_gain	0.2200
X:69161891:G:GA	acceptor_gain	0.2100
X:69161892:A:AA	acceptor_gain	0.2100
X:69161893:A:AA	acceptor_gain	0.2100
X:69163427:AAGG:A	donor_gain	0.2100
X:69162526:A:AC	donor_gain	0.2000
X:69162527:C:CC	donor_gain	0.2000
X:69162747:TGGCC:T	acceptor_gain	0.2000

AlphaMissense

3899 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:69161335:C:T	C635Y	1.000
X:69161336:A:G	C635R	1.000
X:69161343:G:C	C632W	1.000
X:69161344:C:T	C632Y	1.000
X:69161345:A:G	C632R	1.000
X:69161362:A:G	L626P	1.000
X:69161364:C:A	W625C	1.000
X:69161364:C:G	W625C	1.000
X:69161366:A:G	W625R	1.000
X:69161366:A:T	W625R	1.000
X:69161376:A:C	C621W	1.000
X:69161377:C:T	C621Y	1.000
X:69161378:A:G	C621R	1.000
X:69161388:G:C	F617L	1.000
X:69161388:G:T	F617L	1.000
X:69161389:A:G	F617S	1.000
X:69161390:A:G	F617L	1.000
X:69161401:C:T	C613Y	1.000
X:69161402:A:G	C613R	1.000
X:69161407:A:G	L611P	1.000
X:69161445:G:C	C598W	1.000
X:69161446:C:T	C598Y	1.000
X:69161447:A:G	C598R	1.000
X:69161454:G:C	C595W	1.000
X:69161455:C:T	C595Y	1.000
X:69161456:A:G	C595R	1.000
X:69161575:A:G	L555S	1.000
X:69161584:A:G	L552P	1.000
X:69161587:G:T	A551D	1.000
X:69161600:C:G	A547P	1.000

dbSNP variants (sampled 300 via entrez): RS1001541505 (X:69162046 C>A,T), RS1001855452 (X:69167006 A>G), RS1002169974 (X:69166742 C>T), RS1002723963 (X:69165265 C>G,T), RS1002860071 (X:69165507 G>A), RS1003315706 (X:69163221 G>T), RS1003958091 (X:69163244 T>C), RS1004027372 (X:69165710 G>GT), RS1004275192 (X:69164640 G>T), RS1005211585 (X:69167337 T>A), RS1006043710 (X:69160401 T>G), RS1006404444 (X:69160349 A>C), RS1006767177 (X:69161777 C>A,G), RS1007814469 (X:69166471 A>C), RS1008138395 (X:69163780 A>T)

Disease associations

OMIM: gene MIM:300420 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
X-linked complex neurodevelopmental disorder	Moderate	X-linked

Mondo (1): X-linked complex neurodevelopmental disorder (MONDO:0100148)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST002539_98	Schizophrenia	2.000000e-10
GCST006803_26	Schizophrenia	1.000000e-12
GCST008129_36	Body mass index	2.000000e-10
GCST008362_133	Birth weight	4.000000e-10
GCST90002400_2	Plateletcrit	5.000000e-12
GCST90002402_515	Platelet count	3.000000e-14

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0004344	birth weight
EFO:0007985	platelet crit
EFO:0004309	platelet count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
FR900359	affects phosphorylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
beta-lapachone	increases expression	1
sodium arsenite	increases expression	1
manganese chloride	increases abundance, increases expression	1
coumarin	increases phosphorylation	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
Decitabine	increases expression	1
Sunitinib	decreases expression	1
Azacitidine	increases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Cisplatin	increases expression	1
Doxorubicin	decreases expression	1
Manganese	increases abundance, increases expression	1
Methyl Methanesulfonate	increases expression	1
Selenium	increases expression	1
Tretinoin	decreases expression	1
Valproic Acid	increases expression	1
Vitamin E	increases expression	1
Cyclosporine	increases expression	1
Aflatoxin B1	decreases methylation	1
Antirheumatic Agents	increases expression	1
Cadmium Chloride	decreases expression	1
Copper Sulfate	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E2GT	HAP1 PJA1 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.